8 recruiting, 2 completed, 2 withdrawn, 1 active not recruiting. 8 Phase 2, 2 Not applicable, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 4, Withdrawn 2, Completed 1, Unknown 1 |
| Not applicable | 2 | Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow High-risk Prostate Cancer: new trials by email Literature Review of High-risk Prostate Cancer trials Research Report on High-risk Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer Darolutamide, Pembrolizumab, Lupron - Prostate Cancer, High-risk Prostate Cancer | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 40 | 2026-05-21 | 2026-10-07 |
| A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer Neoadjuvant Epigenetic Therapy - High-risk Prostate Cancer | Early Phase 1 | Recruiting | Edwin Posadas, MD | 20 | 2026-04-01 | 2026-02-03 |
| COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) PSMA-11 - Intermediate-risk Prostate Cancer, High-risk Prostate Cancer | Active not recruiting | Heinrich-Heine University, Duesseldorf | 600 | 2026-01-01 | 2026-03-06 | |
| Immunotherapy Before and After Surgery N-803, ETBX-071, M-CENK - High-risk Prostate Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2025-12-15 | 2026-05-05 | |
| Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus), M-CENK (Activated NK Cells) - High-risk Prostate Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2025-12-01 | 2026-05-05 | |
| Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy - Prostate Cancer, Prostate Cancer (Diagnosis) | Phase 1 | Recruiting | Thomas Hope | 45 | 2025-07-08 | 2026-08-28 |
| Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer. Intervention Group - High-risk Prostate Cancer | Not applicable | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 244 | 2025-02-03 | 2026-01-21 |
| FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer FK-PC101, Standard of Care (SOC) - Prostate Cancer (Adenocarcinoma), Prostate CA | Phase 2 | Recruiting | Cellvax Therapeutics Inc | 100 | 2024-10-14 | 2024-10-21 |
| A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss Capivasertib, abiraterone acetate - High-Risk Prostate Cancer | Phase 2 | Recruiting | VA Office of Research and Development | 30 | 2024-05-31 | 2026-10-05 |
| Contribution of Canine Detection in the Diagnostic Strategy of High-risk Prostate Cancer (Prostate-K9-Detect) urine collection, canine detection - High-risk Prostate Cancer | Completed | Assistance Publique - Hôpitaux de Paris | 183 | 2022-11-02 | 2026-08-11 | |
| Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial Abiraterone acetate, Fluzoparib, Prednisone - High-risk Prostate Cancer, Neoadjuvant Therapy | Phase 2 | Unknown | Fudan University | 34 | 2021-05-01 | 2023-12-08 |
| Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer High-risk Prostate Cancer, PSMA PET | Recruiting | Xijing Hospital | 110 | 2021-03-07 | 2026-04-28 | |
| Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery HSV-Tk, Valacyclovir, Bicalutamide - High-risk Prostate Cancer, Prostate Cancer | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 60 | 2018-08-02 | 2021-04-06 |
| Ga-68-PSMA-11 in High-risk Prostate Cancer Ga-68-PSMA-11 - High-risk Prostate Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | German Cancer Research Center | 173 | 2017-10-09 | 2020-07-27 |
| Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients Standard Radiation Treatment, Hypofractionated radiation treatment - High-risk Prostate Cancer | Not applicable | Terminated | AHS Cancer Control Alberta | 111 | 2012-03-01 | 2025-06-29 |
Prostatic Neoplasms (12) · Adenocarcinoma (1) · Disease (1)
Genital Diseases (12) · Genital Diseases, Male (12) · Genital Neoplasms, Male (12) · Male Urogenital Diseases (12) · Neoplasms (12) · Neoplasms by Site (12) · Prostatic Diseases (12) · Urogenital Diseases (12) · Urogenital Neoplasms (12) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
ALT-803 (2) · Abiraterone Acetate (2) · Androgen Antagonists (2) · Leuprolide (2) · Prostatectomy (2) · (225)Ac-PSMA-617 (1) · Blood Specimen Collection (1) · Brachytherapy (1) · Genetic Therapy (1) · Pluvicto (1) · Prednisone (1) · Standard of Care (1) · Urine Specimen Collection (1) · Valacyclovir (1) · bicalutamide (1)
ImmunityBio, Inc. (2) · AHS Cancer Control Alberta (1) · Assistance Publique - Hôpitaux de Paris (1) · Cellvax Therapeutics Inc (1) · Edwin Posadas, MD (1) · Fudan University (1) · German Cancer Research Center (1) · Heinrich-Heine University, Duesseldorf (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Icahn School of Medicine at Mount Sinai (1) · The Methodist Hospital Research Institute (1) · Thomas Hope (1) · VA Office of Research and Development (1) · Xijing Hospital (1)
United States (6) · Austria (2) · China (2) · Germany (2) · Italy (2) · Belgium (1) · Canada (1) · France (1) · India (1) · Sweden (1) · Switzerland (1)
Bruce Brown (2) · Albert Murtha (1) · Ashutosh K Tewari, MD (1) · Dimple Chakravarty, PhD (1) · E. Brian Butler, MD (1) · Edwin Posadas, MD (1) · Fernando Kreutz, MD PhD (1) · Frederik Giesel, Prof. Dr. (1) · Isabelle Busshoff, Dr. med. (1) · Jan Philipp Radtke, Professor Dr. med. (1) · Michela Moscarino, Technician (1) · Peter Albers, Professor Dr. med. (1) · Ryan P Kopp, MD (1) · Thomas A Hope, MD (1)
I01CX002517 (1)